Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Clobetasol propionate + ketoconazole** is a fixed-dose combination topical medication used primarily for the treatment of inflammatory skin conditions complicated by fungal infections. Clobetasol propionate is a potent synthetic corticosteroid that acts as an anti-inflammatory agent by binding to the glucocorticoid receptor, inhibiting pro-inflammatory signals and promoting anti-inflammatory gene expression, leading to reduced swelling, redness, itching, and rashes[1][5]. Ketoconazole is an imidazole antifungal agent that inhibits lanosterol 14-alpha demethylase (a cytochrome P450 enzyme), blocking ergosterol synthesis in fungal cell membranes and increasing membrane permeability, thereby preventing fungal growth[3][8]. This combination targets both inflammation (from steroid-responsive dermatoses such as eczema or psoriasis) and secondary or coexisting superficial fungal infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clobetasol propionate + ketoconazole.